Get the Stockscreener App
8.10
0.25%
0.02
Bioventus Inc stock is traded at $8.10, with a volume of 357.49K.
It is up +0.25% in the last 24 hours and up +4.52% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$8.08
Open:
$8.13
24h Volume:
357.49K
Relative Volume:
1.28
Market Cap:
$542.51M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-13.50
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
-1.34%
1M Performance:
+4.52%
6M Performance:
+10.81%
1Y Performance:
-21.13%
1-Day Range:
$8.01
$8.29
1-Week Range:
$7.78
$9.03
52-Week Range:
$5.81
$11.25
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.10 | 541.17M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
111.47 | 197.52B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
365.85 | 139.09B | 25.12B | 3.25B | 4.28B | 8.4018 |
|
MDT
Medtronic Plc
|
100.88 | 129.59B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
BSX
Boston Scientific Corp
|
74.12 | 108.96B | 20.08B | 2.89B | 3.82B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
76.44 | 46.04B | 6.07B | 1.06B | 799.60M | 1.8527 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-09-26 | Initiated | Barrington Research | Outperform |
| Jul-07-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
Head-To-Head Review: Bioventus (BVS) vs. Its Rivals - Defense World
Chipmakers Recap: Is Bioventus Inc attractive for institutional investors2025 Valuation Update & Weekly High Return Stock Forecasts - baoquankhu1.vn
Recap Report: Is Bioventus Inc currently under institutional pressure2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Bioventus (NASDAQ:BVS) Upgraded at Barrington Research - MarketBeat
Those who invested in Bioventus (NASDAQ:BVS) three years ago are up 413% - Yahoo Finance
Barrington Research Initiates Coverage of Bioventus (BVS) with Outperform Recommendation - Nasdaq
Bioventus (NYSE:BVS) Shares Gap UpWhat's Next? - MarketBeat
Bioventus (NASDAQ:BVS) Shares Gap UpHere's What Happened - MarketBeat
Barrington Initiates Bioventus at Outperform With $13 Price Target - marketscreener.com
Bioventus (NYSE:BVS) Earns Outperform Rating from Analysts at Barrington Research - MarketBeat
This Nokia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Avoiding Lag: Real-Time Signals in (BVS) Movement - Stock Traders Daily
Is Bioventus Inc. attractive for institutional investorsJuly 2025 Snapshot & Technical Pattern Based Buy Signals - baoquankhu1.vn
Bioventus (NASDAQ:BVS) Trading Up 1.4%Here's What Happened - MarketBeat
Bioventus (NASDAQ:BVS) Trading 1.4% HigherWhat's Next? - MarketBeat
Bioventus (NASDAQ:BVS) aligns with Nasdaq Composite Index medtech themes - Kalkine Media
Anderson Financial Strategies LLC Invests $901,000 in Bioventus Inc. $BVS - MarketBeat
Aug Selloffs: Will Bioventus Inc benefit from rising consumer demand2025 Support & Resistance & Reliable Intraday Trade Plans - baoquankhu1.vn
Is Bioventus Inc currently under institutional pressureEarnings Performance Report & Weekly Top Gainers Trade List - baoquankhu1.vn
Discipline and Rules-Based Execution in BVS Response - Stock Traders Daily
US Market Recap: What is Bioventus Incs valuation compared to sectorFed Meeting & Weekly Setup with ROI Potential - baoquankhu1.vn
Entry Recap: Can CNVS maintain sales growthGap Down & Accurate Technical Buy Alerts - baoquankhu1.vn
Published on: 2026-01-23 16:18:52 - baoquankhu1.vn
Bioventus (NYSE:BVS) Trading Up 3.8%Still a Buy? - MarketBeat
Bioventus Details Turnaround Plan, Four Growth Drivers at J.P. Morgan Conference - Defense World
Bioness $110M Sale Suit Heads to $8.9M Deal - Law360
Investment Recap: Is Bioventus Inc in a bullish channel2025 Risk Factors & High Conviction Buy Zone Picks - baoquankhu1.vn
Institutional investors own a significant stake of 36% in Bioventus Inc. (NASDAQ:BVS) - Yahoo Finance
Bioventus (NASDAQ:BVS) Stock Price Down 0.6%Should You Sell? - MarketBeat
Market Catalysts: Is Bioventus Inc currently under institutional pressure2025 Winners & Losers & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Trade Recap: Is Bioventus Inc stock gaining market shareProduct Launch & Safe Capital Preservation Plans - Bộ Nội Vụ
Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year - simplywall.st
What Wall Street predicts for Bioventus Inc. stock priceShort Setup & Weekly Sector Rotation Insights - ulpravda.ru
Why Bioventus Inc. stock could rally in 20252025 Short Interest & Accurate Buy Signal Alerts - Улправда
Will Bioventus Inc. stock deliver consistent dividendsDay Trade & High Accuracy Trade Alerts - Улправда
Is Bioventus Inc. stock gaining market share2025 Earnings Impact & Breakout Confirmation Trade Signals - Улправда
Can Bioventus Inc. stock sustain revenue growthJuly 2025 Spike Watch & Community Consensus Stock Picks - Улправда
How risky is Bioventus Inc. stock nowJuly 2025 Setups & Free Daily Entry Point Trade Alerts - Улправда
Will Bioventus Inc. stock return to pre crisis levelsJuly 2025 Opening Moves & High Accuracy Buy Signal Tips - Улправда
Why Bioventus Inc. stock could outperform in 2025Portfolio Value Summary & Low Risk High Win Rate Picks - Улправда
Hyaluronic Acid Products Market to Reach $20 billion, Globally, - openPR.com
Bioventus to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
(BVS) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
BVS Stock Gains Post Divestiture of Advanced Rehabilitation Business - MSN
Bioventus Inc. (BVS) Stock Analysis: Exploring a 101.61% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
Will Bioventus Inc stock deliver consistent dividends2025 Earnings Impact & Growth Focused Investment Plans - moha.gov.vn
Bioventus (NYSE:BVS) Trading Down 1.1%Time to Sell? - MarketBeat
Why (BVS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Aug Analyst Calls: Why Bioventus Inc stock could outperform in 2025Gap Up & Weekly Breakout Opportunity Watchlist - moha.gov.vn
Why Bioventus Inc. stock is favored by top institutionsJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - Улправда
Will Bioventus Inc. stock benefit from automationJuly 2025 Institutional & Reliable Price Breakout Alerts - DonanımHaber
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.45%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):